Evidence map›Paper›PMID 29685905›Full record

ArticleMolecular and cellular biology2018

Identification of a Novel Invasion-Promoting Region in Insulin Receptor Substrate 2.

Jose Mercado-Matos, Jenny Janusis, Sha Zhu, Samuel S Chen, Leslie M Shaw

Open access · bronzeAbstract read
In one paragraph

Article in Molecular and cellular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Therapeutic delivery of albumin-binding siRNA targeting IRS2 to diverse cell types reduces mammary tumor growth.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Molecular therapy oncolytics · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jose Mercado-MatosDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Jenny JanusisDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Sha ZhuDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Samuel S ChenDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Leslie M ShawDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA leslie.shaw@umassmed.edu.
University of Massachusetts Chan Medical School · US

Funding

IRS-2 Function in Tumor Progression and MetastasisR01CA142782 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SHAW, LESLIE M · 2010 to 2014
$1.6M
The Impact of IRS2-microtubule interactions in the progression of breast cancerF31CA180706 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MERCADO-MATOS, JOSE RAUL · 2013 to 2016
$118k
NCI NIH HHS F31 CA180706NCI NIH HHS R01 CA142782
6 · The paper itself

Abstract

Although the insulin receptor substrate (IRS) proteins IRS1 and IRS2 share considerable homology and activate common signaling pathways, their contributions to breast cancer are distinct. IRS1 has been implicated in the proliferation and survival of breast tumor cells. In contrast, IRS2 facilitates glycolysis, invasion, and metastasis. To determine the mechanistic basis for IRS2-dependent functions, we investigated unique structural features of IRS2 that are required for invasion. Our studies revealed that the ability of IRS2 to promote invasion is dependent upon upstream insulin-like growth factor 1 receptor (IGF-1R)/insulin receptor (IR) activation and the recruitment and activation of phosphatidylinositol 3-kinase (PI3K), functions shared with IRS1. In addition, a 174-amino-acid region in the IRS2 C-terminal tail, which is not conserved in IRS1, is also required for IRS2-mediated invasion. Importantly, this "invasion (INV) region" is sufficient to confer invasion-promoting ability when swapped into IRS1. However, the INV region is not required for the IRS2-dependent regulation of glucose uptake. Bone morphogenetic protein 2-inducible kinase (BMP2K) binds to the INV region and contributes to IRS2-dependent invasion. Taken together, our data advance the mechanistic understanding of how IRS2 regulates invasion and reveal that IRS2 functions important for cancer can be independently targeted without interfering with the metabolic activities of this adaptor protein.

Indexed as

AnimalsBreast NeoplasmsCell Line, TumorFemaleGene Knockout TechniquesGlucoseHumansInsulin Receptor Substrate ProteinsMammary Neoplasms, ExperimentalMiceMice, TransgenicModels, BiologicalMutationNeoplasm InvasivenessPhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesGlucoseInsulin Receptor Substrate ProteinsIRS1 protein, humanIrs1 protein, mouseIRS2 protein, humanIrs2 protein, mousePhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesReceptor, IGF Type 1breast cancerIGF-1RinvasionIRS2PI3K

Identifiers

PMID29685905
PMCPMC6024166
OpenAlexW2801123863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.